Topical platelet-rich plasma as a possible treatment for olfactory dysfunction-A randomized controlled trial

Area of Science:

• Otolaryngology
• Regenerative Medicine
• Infectious Disease Research

Background:

• Olfactory dysfunction (OD) is a common sequela in COVID-19 survivors.
• Platelet-rich plasma (PRP) has been explored for OD treatment.
• This study introduces the first randomized controlled trial (RCT) on topical PRP for post-COVID-19 OD.

Purpose of the Study:

• To evaluate the efficacy of topical platelet-rich plasma (PRP) for treating olfactory dysfunction (OD) in COVID-19 survivors.
• To assess the safety and impact of PRP on smell identification and quality of life.

Main Methods:

• A single-blinded, randomized controlled trial (RCT) involving 83 adult patients with persistent OD post-COVID-19.
• Participants received monthly bilateral olfactory cleft treatments with either PRP or placebo-impregnated foam for 12 months.
• Olfactory function was assessed using the Brief Smell Identification Test (BSIT), SCENTinel, and the Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS).

Main Results:

• PRP treatment led to statistically significant improvements in BSIT scores at specific time points (months 5-9, 11, 12) compared to placebo.
• No significant differences in overall BSIT scores, SCENTinel odor intensity, or QOD-NS scores were observed between the PRP and placebo groups throughout the study.
• PRP recipients reported minor improvements in OD-related quality of life at 12 months.

Conclusions:

• Topical PRP is a safe, experimental therapeutic option for post-COVID-19 olfactory dysfunction.
• PRP may positively influence odor identification in affected patients.
• Further research is warranted to clarify the impact of PRP on overall olfactory function, given the lack of significant difference in total BSIT scores.